Idiopathic Nephrotic Syndrome
13
2
2
7
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 13 trials
100.0%
+13.5% vs benchmark
38%
5 trials in Phase 3/4
14%
1 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (13)
A National Prospective Cohort of Patients With Idiopathic Nephrotic Syndrome Beginning in Childhood.
UrApp for Childhood Nephrotic Syndrome Management (Incident Cohort)
The FOrMe Registry (The German Focal Segmental Glomerulosclerosis and Minimal Change Disease Registry)
Short-term gluCOCOrticoid in Adult STEROID-sensitive Nephrotic Syndrome: The COCO-ASTEROID Study
Reduce Immunosuppression With Atmp in NS ChildrEn
Rituximab for Idiopathic Nephrotic Syndrome
Effect of Daily Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) on Proteinuria in Pediatric Patients With Idiopathic Nephrotic Syndrome
Kidney Disease Biomarkers
Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome
Valproic Acid for Idiopathic Nephrotic Syndrome
Factors of Steroid Dependency in Idiopathic Nephrotic Syndrome
Cyclophosphamide Versus Mycophenolate Mofetil for the Treatment of Steroid-dependent Nephrotic Syndrome in Children
Study of 7-valent Pneumococcal Conjugate Vaccine in Children With Idiopathic Nephrotic Syndrome